Future Opportunities to Leverage the Alzheimer's Disease Neuroimaging Initiative - Workshop Summary
||December 10, 2010
Note: Proceedings contain the opinion of the presenters, but do NOT reflect the conclusions of the Health and Medicine Division or the National Academies. Learn more about the differences between Reports and Proceedings.
Nearly 5.3 million Americans are living with Alzheimer’s disease, and 26.6 million people are affected worldwide. Although a great deal of research and funding has been devoted to understanding Alzheimer’s disease, there is no cure as yet. To improve progress toward this goal, the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a partnership between government, corporations, and philanthropic organizations, seeks to understand better the progression of Alzheimer’s disease and to improve methods for clinical trials of Alzheimer’s treatments. Through its publicly available, international database of clinical and imaging data of elderly control participants, participants with mild cognitive impairment, and patients with Alzheimer’s disease, ADNI fosters research and collaboration on Alzheimer’s research worldwide.
The IOM held a workshop on July 12, 2010, to explore opportunities to leverage the information from and partnerships formed because of ADNI to continue to improve the understanding and treatment of Alzheimer’s disease. Panelists from industry, academia, and government examined the research successes and partnerships formed because of ADNI. They also discussed the benefits and challenges of developing similar international efforts to explore other central nervous system developmental and neurodegenerative disorders. This document summarizes the workshop.